Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-12-06
2003-02-18
Krass, Frederick (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S885000, C514S908000
Reexamination Certificate
active
06521616
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to cancer therapy.
Despite advances in the identification of chemotherapeutic agents for inhibiting the growth of cancer cell, cancer remains a formidable disease with a high mortality rate. A significant problem of chemotherapeutic agents is low specificity. Many anticancer agents do not adequately distinguish normal cells from cancer cells. As a result, they often carry undesirable serious side effects.
SUMMARY OF THE INVENTION
The invention provides a method of inhibiting tumor growth in a mammal with few or no deleterious side effects. The method is carried out by administering to the mammal composition containing an active taurolidine or taurultam compound. The compound is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis. Preferably the compound is administered in a manner and at a dose which preferentially induces apoptotic death compared to necrotic death. A method of treating a tumor of the central nervous system (CNS) is carried out by administering to a mammal a taurolidine or taurultam compound. The compound is administered systemically, e.g., orally or intravenously, or infused directly into the brain or cerebrospinal fluid. An erodible or resorbable solid matrix such as a wafer or sponge is implanted directly into brain tissue. Preferably, the tumor is a glioma, astrocytoma, neuroblastoma, or CNS metastasis from a non-CNS primary tumor. The compound to be administered is taurolidine, taurultam, or a derivative thereof. R is an alkyl, aryl, hydrogen, or hetero group or atom.
Alternatively, the compound is a taurinamide derivative
By derivative of taurolidine or taurultam is meant a sulfonamide compound which possesses at least 10% of the neoplastic activity of taurolidine or taurultam, respectively. A sulfonamide compound is one having a R
2
N—SO
2
R′ formula. Derivatives of the compounds described herein may differ structurally from a reference compound, e.g., taurolidine or taurultam, but preferably retain at least 50% of the biological activity, e.g., induction of apoptotic cell death, of the reference compound. More preferably, a derivative has at least 75%, 85%, 95%, 99% or 100% of the biological activity of the reference compound. In some cases, the biological activity of the derivative may exceed the level of activity of the reference compound. Derivatives may also possess characteristics or activities not possessed by the reference compound. For example, a derivative may have reduced toxicity, prolonged clinical half-life, or improved ability to cross the blood-brain barrier.
The compounds are administered alone or in combination with another antineoplastic agent. Preferably, the coadministered agent kills tumors cells by a mechanism other than apoptosis. For example, an antimetabolite, a purine or pyrimidine analogue, an alkylating agent, crosslinking agent (e.g., a platinum compound), and intercalating agent, and/or an antibiotic is administered in a combination therapy regimen. The coadministered drug is given before, after, or simultaneously with a taurolidine or taurultam compound or a derivative thereof.
The invention also includes treating a drug resistant tumor, e.g., a multiple drug resistant (MDR) tumor, in a mammal by administering to the mammal a taurolidine or taurultam compound. The tumor to be treated is a carcinoma or sarcoma. The drug resistant tumor is selected from the group consisting of a solid tumor, a non-solid tumor, and a lymphoma. For example, the drug resistant tumor is a breast cancer, ovarian cancer, colon cancer, prostate cancer, pancreatic cancer, CNS cancer, liver cancer, lung cancer, urinary bladder cancer, lymphoma, leukemia, or sarcoma.
Any neoplastic cell can be treated using the methods described herein. Preferably, the compound, e.g., taurolidine, taurultam, or a derivative thereof, is administered in a manner which allows direct contact of the surface of the tumor cell. The compound binds to a component, e.g., a cell surface polypeptide ligand or other cell surface moiety to initiate an intracellular signal transduction cascade culminating with cell death by apoptosis. Tumors to be treated include but are not limited to leukemia, lymphoma, breast cancer, ovarian cancer, colon cancer, prostate cancer, pancreatic cancer, CNS cancer, liver cancer, urinary bladder cancer, sarcoma, and melanoma. For example, bladder cancer is treated by inflating the bladder with a solution containing taurolidine, taurultam or a derivative thereof, and skin cancers such as basal cell carcinomas or squamous cell carcinomas are treated by applying the compound formulated as a film, cream, or ointment, directly to the affected skin area. For treatment of primary liver cancers or liver metastases, the compounds are infused into the hepatic artery, portal vein, or other blood vessel of the liver. Alternatively, slow release of the compound to any tissue is accomplished by implanting a drug loaded matrix in direct contact or adjacent to the tumor site.
To purge a mixed population of cells, e.g., a patient derived sample of bone marrow cells or peripheral blood cells, of contaminating cancer cells, the bone marrow cells or peripheral blood cells are cultured in the presence of taurolidine, taurultam, or a derivative thereof. The ex vivo treated cells are then expanded in culture or infused into a mammalian recipient. e.g., the individual from which the cells were derived or another mammalian recipient.
The compounds are formulated for administration to directly contact cancer cells, e.g., in the form of an aqueous solution. Formulations include a therapeutic film-forming composition containing or coated with the therapeutic compound as well as ointments, pastes, sprays, patches, creams, gels, sponges, and foams.
Other features and advantages of the invention will be apparent from the following detailed description and from the claims.
REFERENCES:
patent: 3423408 (1969-01-01), Pfirrmann
patent: 3963706 (1976-06-01), Pfirrmann
patent: 4096241 (1978-06-01), Geistlich et al.
patent: 4107305 (1978-08-01), Pfirrmann
patent: 4226858 (1980-10-01), Pfirrmann
patent: 4337251 (1982-06-01), Pfirrmann
patent: 4587268 (1986-05-01), Geistlich et al.
patent: 4604391 (1986-08-01), Pfirrmann
patent: 4626536 (1986-12-01), Pfirrmann
patent: 4772468 (1988-09-01), Pfirrmann
patent: 5210083 (1993-05-01), Pfirrmann
patent: 5573771 (1996-11-01), Geistlich et al.
patent: 5593665 (1997-01-01), Pfirmann et al.
patent: 5819748 (1998-10-01), Pfirmann
patent: 5954687 (1999-09-01), Baudino
patent: 5972933 (1999-10-01), Pfirmann
patent: 5976822 (1999-11-01), Landrum et al.
patent: 6011030 (2000-01-01), Pfirmann
patent: 6080397 (2000-06-01), Pfirmann et al.
patent: 6117868 (2000-09-01), Pfirmann
patent: 6303596 (2001-10-01), Morrissey et al.
patent: 0253662 (1988-01-01), None
patent: 1066830 (2001-01-01), None
patent: WO 90/06138 (1990-05-01), None
patent: WO 91/13628 (1991-09-01), None
patent: WO 92/00743 (1992-01-01), None
patent: WO 94/03174 (1994-02-01), None
patent: WO 98/52572 (1998-11-01), None
patent: WO 99/06114 (1999-02-01), None
patent: WO 99/34805 (1999-07-01), None
*Jacobi, C. et al, (1999) “Influence of Different Gases and Intraperitoneal Instillation of Antiadherent on Cytotoxic Agents on Peritoneal Tumor Cell Growth and Implantation with Laparoscopic Surgery in a Rat Model,”Surg Endosc, 13: 1021-1025.
International Search Report. PCT/ US 00/33103. Issued on Dec. 13, 2001.
Blenkharn et al. (1987) “The Antibacterial and Anti-Endotoxin Activity of Taurolidine in Combination with Antibiotics,” Surg. Res. Commun., 2:149-155.
Browne M.K. et al. (1985) “Studies on the Antiendotoxin Properties of Taurolin in Animals and Man,”Recent Advances in Chemotherapy, Proceedings of the 14thInternational Congress of Chemotherapy, Kyoto, pp. 2075-2076.
Browne M.K. et al. (1976) “Taurolin, a New Chemotherapeutic Agent,”The Journal of Applied Bacteriology, vol. 41, pp. 363-368.
Geistlich Catalog, “Taurolin, Triad antimicrobial chemotherapy” pp. 1-95, (1989).
Gormans et al. (19
Calabresi Paul
Darnowski James
Beattie, Esq. Ingrid A.
Krass Frederick
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Rhode Island Hospital, A Lifespan Partner
LandOfFree
Methods of treating tumors with taurolidine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating tumors with taurolidine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating tumors with taurolidine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3180426